Stroke is the second most frequent cause of death worldwide and the most frequent cause of permanent disability. Patients with diabetes are at 1.5 to three times the risk of stroke compared with the general population. Cerebrovascular disease causes 20% of deaths in diabetic patients. Interestingly, there are some striking differences of stroke patterns between diabetic and non-diabetic subjects suffering a stroke. Even more important is the fact that diabetes dramatically increases the risk of stroke in younger subjects as well as women. These data highlight the need for detection and treatment of diabetes particularly in these patient groups. This review summarises several aspects of stroke in type 2 diabetes, focusing on differences from non-diabetic stroke.
Murray CJ, Lopez ADMortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet1997; 349:1269-76.
2.
Sacco RL, Benjamin EJ, Broderick JP et al. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke1997; 28:1507-17.
3.
Bell DSStroke in the diabetic patient. Diabetes Care1994; 17:213-19.
4.
Kissela BM, Khoury J., Kleindorfer D. et al. Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care2005; 28:355-9.
5.
Folsom AR, Rasmussen ML, Chambless LE et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care1999; 22:1077-83.
6.
Mankovsky BN , Metzger BE, Molitch ME, Biller J.Cerebrovascular disorders in patients with diabetes mellitus. J Diabetes Complications1996; 10:228-42.
7.
Jorgensen H. , Nakayama H., Raaschou HO, Olsen TSStroke in patients with diabetes. The Copenhagen Stroke Study. Stroke1994; 25:1977-84.
8.
Boden-Albala B., Sacco RL, Lee HS et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke2008 ; 39:30-5.
9.
Arauz A., Murillo L., Cantu C., Barinagarrementeria F., Higuera J.Prospective study of single and multiple lacunar infarcts using magnetic resonance imaging: risk factors, recurrence, and outcome in 175 consecutive cases. Stroke2003; 34:2453-8.
10.
Eguchi K., Kario K., Shimada K.Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts. Stroke2003; 34:2471-4.
11.
Tuttolomondo A., Pinto A., Salemi G. et al. Diabetic and non-diabetic subjects with ischemic stroke: differences, subtype distribution and outcome. Nutr Metab Cardiovasc Dis2008 ; 18:152-7.
12.
Hankey GJ, Jamrozik K., Broadhurst RJ et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke1998; 29:2491-500.
13.
Nannetti L. , Paci M., Baccini M., Rinaldi LA, Taiti PGRecovery from stroke in patients with diabetes mellitus. J Diabetes Complications2008 Apr 14 [Epub ahead of print].
14.
Megherbi SE, Milan C., Minier D. et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke2003; 34:688-94.
15.
Tuomilehto J. , Rastenyte D., Jousilahti P., Sarti C., Vartiainen E.Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke1996; 27:210-15.
16.
Sprafka JM, Virnig BA, Shahar E., McGovern PGTrends in diabetes prevalence among stroke patients and the effect of diabetes on stroke survival: the Minnesota Heart Survey. Diabet Med1994; 11:678-84.
17.
Olsson T., Viitanen M., Asplund K., Eriksson S., Hagg E.Prognosis after stroke in diabetic patients. A controlled prospective study . Diabetologia1990; 33:244-9.
18.
Luchsinger JA , Tang MX, Stern Y., Shea S., Mayeux R.Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multi-ethnic cohort. Am J Epidemiol2001; 154:635-41.
19.
Mulnier HE, Seaman HE, Raleigh VS et al. Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database. Diabetologia2006; 49:2859-65.
20.
Hu G., Sarti C., Jousilahti P. et al. The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke2005; 36:2538-43.
21.
Giorda CB, Avogaro A., Maggini M. et al. Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke2007; 38:1154-60.
22.
Kang SS, Littooy FN, Gupta SR et al. Higher prevalence of abdominal aortic aneurysms in patients with carotid stenosis but without diabetes. Surgery1999; 126:687-91; discussion 691-2.
23.
Ahari A., Bergqvist D., Troeng T. et al. Diabetes mellitus as a risk factor for early outcome after carotid endarterectomy: a population-based study. Eur J Vasc Endovasc Surg1999; 18:122-6.
24.
Kuhan G., Gardiner ED, Abidia AF et al. Risk modelling study for carotid endarterectomy. Br J Surg2001; 88:1590-4.
25.
Poppert H., Wolf O., Theiss W. et al. MRI lesions after invasive therapy of carotid artery stenosis: a risk-modeling analysis. Neurol Res2006; 28:563-7.
26.
Moreno PR, Fuster V.New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol2004; 44:2293-300.
27.
Yokoyama H. , Katakami N., Yamasaki Y.Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke2006; 37:2420-7.
28.
Tiehuis AM, van der Graaf Y., Visseren FL et al. Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke2008; 39:1600-03.
29.
Honda M., Kitagawa N., Tsutsumi K. et al. High-resolution magnetic resonance imaging for detection of carotid plaques. Neurosurgery2006; 58:338-46; discussion 338-46.
30.
Esposito L. , Sievers M., Sander D. et al. Detection of unstable carotid artery stenosis using MRI. J Neurol2007; 254:1714-22.
31.
Takaya N., Yuan C., Chu B. et al. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI: initial results. Stroke2006; 37: 818-23.
32.
Lin K., Zhang ZQ, Detrano R., Lu B., Fan ZMCarotid vulnerable lesions are related to accelerated recurrence for cerebral infarction magnetic resonance imaging study. Acad Radiol2006; 13:1180-6.
33.
Esposito L. , Heider P., Wolf O. et al. Carotid artery stenosis: diagnosis of diabetes predicts increased vulnerability of plaques irrespective of the degree of stenosis. Cerebrovasc Dis2008; 25:20.
34.
Stevens RJ, Coleman RL, Adler AI et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care2004; 27:201-07.
35.
Epstein M., Sowers JRDiabetes mellitus and hypertension. Hypertension1992; 19:403-18.
36.
Dahlof B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity hypertension study (LIFE): a randomised trial against atenolol. Lancet2002; 359:995-1003.
37.
Julius S., Kjeldsen SE, Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004; 363:2022-31.
38.
Elliott WJ, Meyer PMIncident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet2007; 369:201-07.
39.
Yusuf S., Teo KK, Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med2008; 358:1547-59.
40.
Benjamin EJ , Levy D., Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PAIndependent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA1994; 271:840-4.
41.
Lakshminarayan K., Anderson DC, Herzog CA, Qureshi AIClinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States . Neurologist2008; 14:143-50.
42.
Smith PJ, Hurlen M., Abdelnoor M., Arnesen H.Less benefit from warfarin in diabetics after myocardial infarction?Cardiology2008; 111:161-6.
43.
Sacco RL, Adams R., Albers G. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation2006; 113:e409-e449.
44.
Wang TJ, Parise H., Levy D. et al. Obesity and the risk of new-onset atrial fibrillation. JAMA2004; 292:2471-17.
45.
Shelgikar KM , Hockaday TD, Yajnik CSCentral rather than generalized obesity is related to hyperglycaemia in Asian Indian subjects . Diabet Med1991; 8:712-17.
46.
Mozaffarian D., Marfisi R., Levantesi G., et al. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet2007; 370:667-75.
47.
Tanne D., Koren-Morag N., Goldbourt U.Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks: a prospective cohort study. Stroke2004; 35:2351-5.
48.
Capes SE, Hunt D., Malmberg K., Pathak P., Gerstein HCStress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke2001 ; 32:2426-32.
49.
Selvin E., Marinopoulos S., Berkenblit G. et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med2004; 141:421-31.
50.
Batty GD, Kivimaki M., Davey Smith G., Marmot MG, Shipley MJPost-challenge blood glucose concentration and stroke mortality rates in non-diabetic men in London: 38-year follow-up of the original Whitehall prospective cohort study. Diabetologia2008 ; 51:1123-6.
51.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).UK Prospective Diabetes Study (UKPDS) Group . Lancet1998; 352:854-65.
52.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group . Lancet. 1998; 352:837-53.
53.
Lehto S., Ronnemaa T., Pyorala K., Laakso M.Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes . Stroke1996; 27:63-8.
54.
Sacco RL, Benson RT, Kargman DE et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA2001; 285:2729-35.
55.
Amarenco P. , Labreuche J., Touboul PJHigh-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis2008; 196:489-96.
56.
Corvol JC, Bouzamondo A., Sirol M., Hulot JS, Sanchez P., Lechat P.Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
57.
Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004; 364:685-96.
58.
Keech A., Colquhoun D., Best J. et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care2003; 26:2713-21.
59.
MRC/BHFHeart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002; 360:7-22.
60.
Amarenco P., Bogousslavsky J., Callahan A. 3rd et al. High-dose atorvastatin after stroke or transient ischemic attack . N Engl J Med2006; 355:549-59.
61.
Collaborators Cttc, Kearney PM, Blackwell L. et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis . Lancet2008; 371:117-25.
62.
Pyorala M., Miettinen H., Laakso M., Pyorala K.Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Stroke1998; 29:1860-6.
63.
Matsumoto K. , Miyake S., Yano M. et al. Insulin resistance and classic risk factors in type 2 diabetic patients with different subtypes of ischemic stroke . Diabetes Care1999; 22:1191-5.
64.
Najarian RM , Sullivan LM, Kannel WB, Wilson PW, D'Agostino RB, Wolf PAMetabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med2006; 166:106-11.
65.
Meerarani P. , Badimon JJ, Zias E., Fuster V., Moreno PRMetabolic syndrome and diabetic atherothrombosis: implications in vascular complications. Curr Mol Med2006; 6:501-14.
66.
Bots ML, Hoes AW, Koudstaal PJ, Hofman A., Grobbee DECommon carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation1997; 96:1432-7.
67.
Henry RM, Kostense PJ, Dekker JM et al. Carotid arterial remodeling: a maladaptive phenomenon in type 2 diabetes but not in impaired glucose metabolism: the Hoorn study. Stroke2004; 35:671-6.
68.
Wagenknecht LE, D'Agostino R. Jr, Savage PJ, O'Leary DH, Saad MF, Haffner SMDuration of diabetes and carotid wall thickness. The Insulin Resistance Atherosclerosis Study (IRAS) . Stroke1997; 28: 999-1005.
69.
Howard BV, Roman MJ, Devereux RB et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA2008; 299:1678-89.
70.
Gillett M., Davis WA, Jackson D., Bruce DG, Davis TMProspective evaluation of carotid bruit as a predictor of first stroke in type 2 diabetes: the Fremantle Diabetes Study. Stroke2003; 34:2145-51.
71.
Cheung N., Rogers S., Couper DJ, Klein R., Sharrett AR, Wong TYIs diabetic retinopathy an independent risk factor for ischemic stroke?Stroke2007; 38:398-401.
72.
Lehto S., Niskanen L., Ronnemaa T., Laakso M.Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke1998; 29:635-9.
73.
Guerrero-Romero F., Rodriguez-Moran M.Proteinuria is an independent risk factor for ischemic stroke in non-insulin-dependent diabetes mellitus . Stroke1999; 30:1787-91.
74.
Wannamethee SG, Shaper AG, Perry IJSerum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke1997; 28:557-63.
75.
You RX, McNeil JJ, O'Malley HM, Davis SM, Thrift AG, Donnan GARisk factors for stroke due to cerebral infarction in young adults . Stroke1997; 28:1913-18.
Idris I., Thomson GA, Sharma JCDiabetes mellitus and stroke. Int J Clin Pract2006; 60:48-56.
78.
Johnston SC , Rothwell PM, Nguyen-Huynh MN et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet2007; 369:283-92.
79.
Fateh-Moghadam S., Plockinger U., Cabeza N. et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol2005; 42:99-103.
80.
Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RIInsulin resistance and risk for stroke. Neurology2002; 59:809-15.
81.
Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RAA randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes . Am Heart J2007; 153:445e1-e6.
82.
Kernan WN, Inzucchi SE, Viscoli CM et al. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke2003; 34:1431-6.
83.
Takano H., Hasegawa H., Zou Y., Komuro I.Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des2004 ; 10:2779-86.
84.
Nakamura T. , Yamamoto E., Kataoka K. et al. Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke2007; 38:3016-22.
85.
Kielian T., Drew PDEffects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J Neurosci Res2003; 71:315-25.
86.
Tureyen K., Kapadia R., Bowen KK et al. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem2007; 101:41-56.
87.
Wilcox R., Bousser MG, Betteridge DJ et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke2007; 38:865-73.
88.
Dormandy JA , Charbonnel B., Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet2005; 366:1279-89.
89.
Lincoff AM, Wolski K., Nicholls SJ, Nissen SEPioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA2007; 298:1180-8.
